Mycophenolate mofetil to the rescue in autoimmune hepatitis: A fresh sprout on the decision tree

Journal of Hepatology

Volumn 51, Issue 1, 2009, Pages 8-10

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ALOPECIA; AUTOIMMUNE HEPATITIS; CLINICAL PROTOCOL; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; HEADACHE; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MEDICAL DECISION MAKING; NAUSEA; NEUTROPENIA; PANCREATITIS; PATIENT CARE; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID;

EID: 67349236642     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.03.011     Document Type: Editorial

References (31)

1. Kanzler S., Lohr H., Gerken G., Galle P.R., and Lohse A.W. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol 39 (2001) 339-348
2. Floreani A., Niro G., Rosa Rizzotto E., Antoniazzi S., Ferrara F., Carderi I., et al. Type 1 autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther 24 (2006) 1051-1057
3. Seo S., Toutounjian R., Conrad A., Blatt L., and Tong M.J. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol 23 (2008) 1410-1414
4. Czaja A.J. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 51 (2009) 161-167
5. Roberts S.K., Therneau T., and Czaja A.J. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 110 (1996) 848-857
6. Czaja A.J., and Carpenter H.A. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 40 (2004) 644-650
7. Gregorio G.V., Portmann B., Reid F., Donaldson P.T., Doherty D.G., McCartney M., et al. Autoimmune hepatitis in childhood. A 20 year survey. Hepatology 25 (1997) 541-547
8. Yachha S.K., Srivastava A., Chetri K., Saraswat V.A., and Krishnani N. Autoimmune liver disease in children. J Gastroenterol Hepatol 16 (2001) 674-677
9. Saadah O.I., Smith A.L., and Hardikar W. Long-term outcome of autoimmune hepatitis in children. J Gastroenterol Hepatol 16 (2001) 1297-1302
10. Aw M.M., Dhawan A., Samyn M., Bargiota A., and Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: A 5-year follow-up. J Hepatol 51 (2009) 156-160
11. Montano-Loza A.J., Carpenter H.A., and Czaja A.J. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end stage liver disease. Hepatology 46 (2007) 1138-1145
12. Czaja AJ. Features and consequences of untreated autoimmune hepatitis. Liver Int 2008 Oct 14. [Epub ahead of print].
13. Becker B.N. Mycophenolate mofetil. Transplant Proc 31 (1999) 2777-2778
14. Allison A.C., and Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47 (2000) 85-118
15. Cohn R.G., Mirkovich A., Dunlap B., Burton P., Chiu S.H., Eugui E., et al. Mycophenolate acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 68 (1999) 411-418
16. Mehling A., Grabbe S., and Voskort M. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 165 (2000) 2374-2381
17. Czaja A.J., and Carpenter H.A. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 39 (2005) 819-825
18. Richardson P.D., James P.D., and Ryder S.D. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine. J Hepatol 33 (2000) 371-375
19. Devlin S.M., Swain M.G., Urbanski S.J., and Burak K.W. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 18 (2004) 321-326
20. Chatur N., Ramji A., Bain V.G., Ma M.M., Marotta P.J., Ghent C.N., et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian Association for the Study of Liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 25 (2005) 723-727
21. Inductivo-Yu I., Adams A., Gish R.G., Wakil A., Bzowej N.H., Frederick R.T., et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 5 (2007) 799-802
22. Hlivko J.T., Shiffman M.L., Stravitz R.T., Luketic V.A., Sanyal A.J., Fuchs M., et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 6 (2008) 1036-1040
23. Hennes E.M., Oo Y.H., Schramm C., Denzer U., Buggisch P., Wiegard C., et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?. Am J Gastroenterol 103 (2008) 3063-3070
24. Wolf DC, Bojito L, Facciuto M, Lebovics E. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci, 2008 Dec 12 [Epub ahead of print].
25. Czaja A.J. Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 11 (1990) 1044-1049
26. Johnson P.J., McFarlane I.G., and Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 333 (1995) 958-963
27. Seikaly M.G. Mycophenolate mofetil-is it worth the cost? The in-favor opinion. Pediatr Transplant 3 (1999) 79-82
28. Heneghan M.A., Al-Chalabi T., and McFarlane I.G. Cost-effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother 7 (2006) 145-156
29. Tse K.C., Tang C.S., Lam M.F., Yap D.Y., and Chan T.M. Cost comparison between mycophenolate mofetil and cyclophoshamide-azathioprine in the treatment of lupus nephritis. J Rheumatol 36 (2009) 76-81
30. Sterling R.K., Savatori J.J., Luketic V.A., Sanyal A.J., Fulcher A.S., Stravitz R.T., et al. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of sclerosing cholangitis. Aliment Pharmacol Ther 20 (2004) 943-949
31. Talwalkar J.A., Angulo P., Keach J.C., Petz J.L., Jorgensen R.A., and Lindor K.D. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 100 (2005) 308-312